Work

Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).

Year: 2010

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2010.28.18_suppl.3

Authors: Y. Bang, E. L. Kwak, A. T. Shaw, D. R. Camidge, A. J. Iafrate, R. G. Maki, B. J. Solomon, S. I. Ou, R. Salgia, J. W. Clark

Institutions: Memorial Sloan Kettering Cancer Center, Seoul National University, Peter MacCallum Cancer Centre, Seoul National University Hospital, Massachusetts General Hospital, University of California, Irvine Medical Center, University of Colorado Denver

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589957652

Cites:

Cited by: 134

Related to: 10